Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Drops By 68.0%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 38,900 shares, a drop of 68.0% from the February 13th total of 121,400 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 153,700 shares, the days-to-cover ratio is presently 0.3 days.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of institutional investors have recently made changes to their positions in BOLT. Millennium Management LLC bought a new position in shares of Bolt Biotherapeutics in the fourth quarter worth about $25,000. Squarepoint Ops LLC bought a new position in Bolt Biotherapeutics in the 4th quarter worth approximately $26,000. Velan Capital Investment Management LP bought a new position in Bolt Biotherapeutics in the 4th quarter worth approximately $27,000. Citadel Advisors LLC bought a new position in Bolt Biotherapeutics during the fourth quarter worth $42,000. Finally, FMR LLC increased its position in Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after acquiring an additional 28,773 shares during the period. 86.70% of the stock is currently owned by institutional investors.

Bolt Biotherapeutics Stock Performance

BOLT traded down $0.00 during trading on Friday, hitting $0.41. The stock had a trading volume of 90,785 shares, compared to its average volume of 170,031. The firm has a market cap of $15.85 million, a PE ratio of -0.24 and a beta of 0.94. Bolt Biotherapeutics has a 12 month low of $0.39 and a 12 month high of $1.56. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. The company has a 50 day simple moving average of $0.49 and a 200-day simple moving average of $0.57.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.